The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
 
Margaret K. Callahan
Employment - Bristol-Myers Squibb (I); Celgene (I)
Consulting or Advisory Role - AstraZeneca
Research Funding - Bristol-Myers Squibb (Inst)
 
Brooke Elizabeth Kania
No Relationships to Disclose
 
Gopa Iyer
No Relationships to Disclose
 
Jessica Mary Clement
Consulting or Advisory Role - Anthem
Travel, Accommodations, Expenses - Anthem
 
Samuel Funt
Stock and Other Ownership Interests - Kite, a Gilead company
 
Asia S. McCoy
No Relationships to Disclose
 
Grace Hettich
No Relationships to Disclose
 
Etay Ziv
No Relationships to Disclose
 
Mark J. Bluth
No Relationships to Disclose
 
Phillip Wong
Consulting or Advisory Role - Merck
Patents, Royalties, Other Intellectual Property - Receive small annual royalty payments from the University of Washington for a monoclonal antibody that was developed during my graduate studies there.
 
Jedd D. Wolchok
Stock and Other Ownership Interests - Potenza Therapeutics; Vesuvius Pharmaceuticals
Consulting or Advisory Role - Advaxis; Beigene; Bristol-Myers Squibb; F-Star; Genentech; Jounce Therapeutics; Lilly; MedImmune; Merck; Polaris; Polynoma; Potenza Therapeutics; Sellas Life Sciences; Tizona Therapeutics, Inc.; ZIOPHARM Oncology
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for use of oncolytic Newcastle Disease virus.; I am a co-inventor on an issued patent for DNA vaccines for treatment of cancer in companion animals.
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Dean F. Bajorin
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Lilly; Merck; Novartis; Roche; Roche/Genentech; Urogen pharma
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Roche/Genentech
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche